Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy

CONCLUSIONS: Our results reinforce the tafamidis efficacy to treat A-ATTRv-PNP if started early in the disease course. Patients with the V30M variant, NIS<15 and PND I are the most appropriate subjects for this treatment.PMID:38556397 | DOI:10.1016/j.medcli.2024.01.008

https://pubmed.ncbi.nlm.nih.gov/38556397/?utm_source=no_user_agent&utm_medium=rs...

Source: Medicina Clinica - March 31, 2024 Category: General Medicine Authors: Maria Antonia Ribot Sanso Adri án Rodriguez Rodriguez Laura Mart ínez Vicente Teresa Sevilla Cristina Borrachero Garro Julian Fern ández Martín Adri án Antón Vicente Moises Morales de la Prida Luc ía Galán Dávila Laura Gonz ález Vázquez Ferran Source Type: research